The cure for cancer
-Canada
The cure we have always been wishing for has been around for quite sometime, the cure for cancer. As millions of people are diagnosed and dies from cancer everyday, there is finally hope. Coming from brilliant scientist of the University of Alberta in Edmunton, Canada they discovered that DCA, which is an odourless, colourless, inexpensive, relatively non-toxic, small molecule can cure cancer. Although, it is not yet being used to cure cancer, researchers at the University of Alberta believe it may soon be used as an effective treatment for many forms of cancer.
It is known as, Dichloroacetate (DCA), which causes regression in several cancers, including lung, breast, and brain tumors. Mitochondria, the energy producing units in cells, have been treated by Scientists and doctors for over decades, by usings DCA to treat children with inborn errors of metabolism due to mitochondrial diseases. Mitochondria have been connected with cancer since the 1930s, when researchers first noticed that these organelles dysfunction when cancer is present.
DCA, activates a critical mitochondrial enzyme, as a way to “revive” cancer-affected mitochondria. It also, unlike most currently used chemotherapies, does not have any effects on normal, non-cancerous tissues.
Dr. Evangelos Michelakis, a professor at the U of A Department of Medicine, says, ”I think DCA can be selective for cancer because it attacks a fundamental process in cancer development that is unique to cancer cells,” Michelakis said. “One of the really exciting things about this compound is that it might be able to treat many different forms of cancer”.
Being that DCA is so small, it is easily absorbed in the body, and, after oral intake, it can reach areas in the body that other drugs cannot, making it possible to treat brain cancers.
This particular compound is not patent and not owned by any pharmaceutical company, therefore, would likely be an inexpensive drug to administer, says Michelakis, the Canada Research Chair in Pulmonary Hypertension and Director of the Pulmonary Hypertension Program with Capital Health, one of Canada’s largest health authorities. Michelakis is also concerned that it may be difficult to find funding from private investors to test DCA in clinical trials.
Michelakis is grateful for the support he has already received from publicly funded agencies, such as the Canadian Institutes for Health Research (CIHR), and he is hopeful such support will continue and allow him to conduct clinical trials of DCA on cancer patients.
Michelakis’ research is currently funded by the CIHR, the Canada Foundation for Innovation, the Canada Research Chairs program, and the Alberta Heritage Foundation for Medical Research.
http://www.dca.med.ualberta.ca/Home/Updates/2007-03-15_Update.cfm

